Key facts
- Dassault Systèmes is in talks to acquire ArisGlobal, a drug trial software maker.
- The potential deal is valued at around $2 billion, including $1.8 billion in cash and $200 million in payouts.
- ArisGlobal is being sold by Nordic Capital, a Swedish private equity group.
- This acquisition would be Dassault Systèmes' second-largest, after the 2019 purchase of Medidata Solutions for $5.8 billion.
- Dassault Systèmes reported first-quarter revenue of 1.51 billion euros ($1.77 billion) in April 2024.
French software maker Dassault Systèmes is reportedly in discussions to acquire ArisGlobal, a company specializing in drug trial software, from Swedish private equity firm Nordic Capital for approximately $2 billion. The proposed deal includes $1.8 billion in cash and an additional $200 million in potential payouts.
This strategic move aims to bolster Dassault Systèmes' presence in the life sciences sector, building on its previous significant acquisition of clinical trial software group Medidata Solutions for $5.8 billion in 2019. The company, which provides software to various industries including automotive and aerospace, has been increasingly focusing on augmented AI and data centers for growth amid a slowdown in the global auto industry.
In April, Dassault Systèmes reported first-quarter revenue of 1.51 billion euros ($1.77 billion), which was in line with estimates. However, the acquisition of ArisGlobal is not yet confirmed, as negotiations are ongoing and could potentially fall apart.